Anti-KRAS T cell transfer. Adaptive cell therapies, such as tumor-infiltrated lymphocytes (TILs) therapy, engineered T cell receptor (TCR) therapy and chimeric antigen receptor T cell therapy, have made impressive progress in melanoma, sarcoma and B cell lymphomas in the last decade 44-47. The gene discussed is KRAS; the disease is neoplasm.